How to appeal a UnitedHealthcare pulmonary hypertension denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for pulmonary hypertension

Cited policy: OptumRx Winrevair (Sotatercept) Prior Authorization (Policy #2024D0099B)

Diagnosis WHO Group 1 PAH confirmed by RHC (mPAP ≥20 mmHg, PCWP ≤15, PVR ≥2 WU). WHO FC II or III. On stable background PAH therapy ≥3 mo (commonly ERA + PDE5i ± prostacyclin). Prescribed by PH specialist at PHA-accredited center. Hgb monitoring per REMS. Reauth at 6 mo with 6MWD/FC/NT-proBNP/REVEAL improvement.

How UnitedHealthcare denies pulmonary hypertension — and how to counter it

Where UnitedHealthcare pushes back: 1) Must fail triple oral first; 2) Sotatercept experimental / too new; 3) STELLAR enrolled stable patients only — not for high-risk; 4) Background therapy not optimized.

Counter-arguments that hold up: Winrevair FDA-approved Mar 26, 2024 PAH FC II–III on background therapy — NOT investigational. STELLAR Hoeper NEJM 2023;388(16):1478-1490 — Phase 3 n=323, 6MWD +40.8 m vs placebo, NT-proBNP −229 pg/mL, PVR −165 dyn·s·cm⁻⁵, 84% of trial patients on background triple. ZENITH (high-risk FC III/IV) and HYPERION (newly diagnosed) extensions. ESC/ERS 2022 + 7th World Symposium 2024 endorse activin signaling pathway as fourth treatment pillar. First new PAH mechanism in 16 years.

What UnitedHealthcare typically denies for pulmonary hypertension

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For pulmonary hypertension, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the pulmonary hypertension treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Winrevair (sotatercept)
• Opsumit (macitentan)
• Letairis (ambrisentan)
• Tracleer (bosentan)
• Adcirca/Alyq (tadalafil)
• Revatio (sildenafil)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.